The US FDA has just given Orphan status to the ALS treatment being developed by Israel’s Kadimastem (see here). The designation qualifies the company for various development incentives and less rigorous bureaucracy. Kadimastem expects results of its Israeli clinical trials in mid-2019.
https://www.calcalistech.com/ctech/articles/0,7340,L-3749031,00.html